Chimeric Antigen Receptor (CAR) T cell therapy for Glioblastoma

Publication date: Available online 15 July 2017
Source:Translational Research
Author(s): Analiz Rodriguez, Christine Brown, Behnam Badie
Chimeric antigen receptor (CAR) T cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma (GBM) continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy. Identification of appropriate glioma-associated antigens, barriers to cell delivery, and presence of an immunosuppressive micro-environment are factors that make CAR T cell therapy for GBM particularly challenging. However, insights gained from preclinical studies and on-going clinical trials indicate that CAR T cell therapy will continue to evolve and likely become integrated with current therapeutics strategies for malignant glioma.



from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2v4QOzl
via IFTTT